HealthcareFirms.com » Auto-Immunine Disorders http://healthcarefirms.com The Healthcare Industry Website Directory - Coming Soon Sat, 05 Feb 2011 02:14:44 +0000 en hourly 1 http://wordpress.org/?v=3.2.1 Geron Corporation http://healthcarefirms.com/geron-corporation/ http://healthcarefirms.com/geron-corporation/#comments Tue, 02 Mar 2010 18:40:16 +0000 admin Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials in different cancers.

]]> http://healthcarefirms.com/geron-corporation/feed/ 0 Pharmacyclics Inc. http://healthcarefirms.com/pharmacyclics-inc/ http://healthcarefirms.com/pharmacyclics-inc/#comments Tue, 02 Mar 2010 18:40:16 +0000 admin Pharmacyclics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The Company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics’ business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commercialization of its products. The Company is headquartered in Sunnyvale, California.

]]> http://healthcarefirms.com/pharmacyclics-inc/feed/ 0 Vertex Pharmaceuticals http://healthcarefirms.com/vertex-pharmaceuticals/ http://healthcarefirms.com/vertex-pharmaceuticals/#comments Tue, 02 Mar 2010 18:40:16 +0000 admin Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company’s strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex’s product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain.

]]> http://healthcarefirms.com/vertex-pharmaceuticals/feed/ 0 Lescarden Inc. http://healthcarefirms.com/lescarden-inc/ http://healthcarefirms.com/lescarden-inc/#comments Tue, 02 Mar 2010 18:40:16 +0000 admin Lescarden Incorporated is a biotechnology company dedicated to the research and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis, autoimmune and cancer applications. Lescarden

]]> http://healthcarefirms.com/lescarden-inc/feed/ 0 Ardea Biosciences, Inc. http://healthcarefirms.com/ardea-biosciences-inc/ http://healthcarefirms.com/ardea-biosciences-inc/#comments Fri, 26 Feb 2010 18:31:21 +0000 admin Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus. RDEA594, its lead product candidate in development for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Its next-generation URAT1 inhibitor, RDEA684, is currently in preclinical development. RDEA119, a potent and specific inhibitor of mitogen-activated ERK kinase (MEK), is being developed under a global license agreement with Bayer HealthCare AG.

]]> http://healthcarefirms.com/ardea-biosciences-inc/feed/ 0 Biodel Inc. http://healthcarefirms.com/biodel-inc/ http://healthcarefirms.com/biodel-inc/#comments Fri, 26 Feb 2010 18:31:21 +0000 admin Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders such as diabetes. Biodel’s product candidates are developed using VIAdelTM technology, which reformulates existing FDA-approved peptide drugs.

]]> http://healthcarefirms.com/biodel-inc/feed/ 0 PDL BioPharma, Inc. http://healthcarefirms.com/pdl-biopharma-inc/ http://healthcarefirms.com/pdl-biopharma-inc/#comments Sun, 21 Feb 2010 18:37:26 +0000 admin PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products.

]]> http://healthcarefirms.com/pdl-biopharma-inc/feed/ 0 Opexa Therapeutics, Inc. http://healthcarefirms.com/opexa-therapeutics-inc/ http://healthcarefirms.com/opexa-therapeutics-inc/#comments Sun, 21 Feb 2010 13:59:35 +0000 admin Opexa Therapeutics, Inc. is dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases. The Company’s leading therapy, Tovaxin®, is an individualized cellular immunotherapy treatment in Phase IIb clinical development for multiple sclerosis (MS). Tovaxin is derived from T-cells isolated from peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin and, thereby, reduces the risk of relapse over time.

]]> http://healthcarefirms.com/opexa-therapeutics-inc/feed/ 0 La Jolla Pharmaceutical Co. http://healthcarefirms.com/la-jolla-pharmaceutical-co/ http://healthcarefirms.com/la-jolla-pharmaceutical-co/#comments Sun, 21 Feb 2010 13:59:34 +0000 admin La Jolla Pharmaceutical Company is dedicated to improving and preserving human life by developing innovative pharmaceutical products. The Company has historically focused on the development and testing of Riquent® (abetimus sodium), as a treatment for patients with lupus. Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. The Company has also developed small molecules to treat various other autoimmune and inflammatory conditions.

]]> http://healthcarefirms.com/la-jolla-pharmaceutical-co/feed/ 0 Lexicon Pharmaceuticals, Inc. http://healthcarefirms.com/lexicon-pharmaceuticals-inc/ http://healthcarefirms.com/lexicon-pharmaceuticals-inc/#comments Sun, 21 Feb 2010 13:59:34 +0000 admin Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.  Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon’s research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.

]]> http://healthcarefirms.com/lexicon-pharmaceuticals-inc/feed/ 0 MannKind Corp. http://healthcarefirms.com/mannkind-corp/ http://healthcarefirms.com/mannkind-corp/#comments Sun, 21 Feb 2010 13:59:34 +0000 admin MannKind Corporation focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFREZZA(TM) (formerly AFRESA(R)), MKC253, MKC1106-PP, and MKC1106-MT. MannKind has submitted an NDA to the FDA requesting approval of AFREZZA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The other three programs are currently in Phase 1 clinical trials.

]]> http://healthcarefirms.com/mannkind-corp/feed/ 0 Micromet, Inc. http://healthcarefirms.com/micromet-inc/ http://healthcarefirms.com/micromet-inc/#comments Sun, 21 Feb 2010 13:59:34 +0000 admin Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet’s BiTE antibodies and three of its conventional antibodies are currently in clinical trials.  Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed.

]]> http://healthcarefirms.com/micromet-inc/feed/ 0 NPS Pharmaceuticals, Inc. http://healthcarefirms.com/nps-pharmaceuticals-inc/ http://healthcarefirms.com/nps-pharmaceuticals-inc/#comments Sun, 21 Feb 2010 13:59:34 +0000 admin NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently conducting two Phase 3 registration studies. Teduglutide, a proprietary analog of GLP-2, is being evaluated as GATTEX(R) in a Phase 3 registration study known as STEPS for intestinal failure associated with short bowel syndrome and in preclinical development for chemotherapy-induced gastrointestinal mucositis and other pediatric indications. NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is being evaluated in a Phase 3 registration study known as REPLACE as a hormone replacement therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, Kyowa Kirin, Nycomed, and Ortho-McNeil-Janssen Pharmaceuticals.

]]> http://healthcarefirms.com/nps-pharmaceuticals-inc/feed/ 0 Celldex Therapeutics, Inc. http://healthcarefirms.com/celldex-therapeutics-inc/ http://healthcarefirms.com/celldex-therapeutics-inc/#comments Sat, 20 Feb 2010 18:16:31 +0000 admin Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates.

]]> http://healthcarefirms.com/celldex-therapeutics-inc/feed/ 0 Immunomedics Inc. http://healthcarefirms.com/immunomedics-inc/ http://healthcarefirms.com/immunomedics-inc/#comments Sat, 20 Feb 2010 18:16:31 +0000 admin Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. Immunomedics developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or

]]> http://healthcarefirms.com/immunomedics-inc/feed/ 0 Human Genome Sciences Inc. http://healthcarefirms.com/human-genome-sciences-inc/ http://healthcarefirms.com/human-genome-sciences-inc/#comments Wed, 17 Feb 2010 12:38:22 +0000 admin The HGS clinical development pipeline includes novel drugs to treat lupus, hepatitis C, inhalation anthrax and cancer. 

The Company’s primary focus is rapid progress toward the commercialization of its two lead drugs, BENLYSTA™ (belimumab) for lupus and ZALBIN™ (albinterferon alfa-2b) for hepatitis C. Phase 3 development has been completed successfully for both BENLYSTA and Zalbin. The submission of marketing applications for BENLYSTA is planned in the U.S., Europe and other regions in the first half of 2010. A BLA has been submitted for ZALBIN to the FDA in the United States, and an MAA has been submitted under the brand name JOULFERON® to the EMEA in Europe.

]]> http://healthcarefirms.com/human-genome-sciences-inc/feed/ 0 Immunosyn Corporation http://healthcarefirms.com/immunosyn-corporation/ http://healthcarefirms.com/immunosyn-corporation/#comments Wed, 17 Feb 2010 12:38:22 +0000 admin Immunosyn is a development stage marketing and distribution company. Our headquarter offices are located in La Jolla, CA, with a regional office in Chicago, IL and a Scientific Advisory Board that is globally positioned. Our first product to be introduced, currently called SF-1019, is believed by our Scientific Advisory Board to be one of a new class of therapeutics made from mammalian cells that may have the ability to dramatically affect many auto-immune, neurological and demyelinating conditions resulting in a rapid reduction of symptoms. SF-1019 will be marketable upon receipt of potential regulatory approval in the appropriate jurisdictions.

]]> http://healthcarefirms.com/immunosyn-corporation/feed/ 0 Incyte Corporation http://healthcarefirms.com/incyte-corporation/ http://healthcarefirms.com/incyte-corporation/#comments Wed, 17 Feb 2010 12:38:22 +0000 admin Incyte Corporation is a Wilmington, Delaware-based drug discovery and development company focused on developing proprietary small molecule drugs for oncology, inflammation and diabetes. Incyte’s most advanced compound, INCB18424, is in Phase III development for myelofibrosis.

]]> http://healthcarefirms.com/incyte-corporation/feed/ 0 Idera Pharmaceuticals, Inc. http://healthcarefirms.com/idera-pharmaceuticals-inc/ http://healthcarefirms.com/idera-pharmaceuticals-inc/#comments Wed, 17 Feb 2010 12:38:22 +0000 admin Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors (TLRs), which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for our internal development programs and our partnered programs, and generates opportunities for additional collaborative alliances.

]]> http://healthcarefirms.com/idera-pharmaceuticals-inc/feed/ 0 Hemispherx Biopharma, Inc. http://healthcarefirms.com/hemispherx-biopharma-inc/ http://healthcarefirms.com/hemispherx-biopharma-inc/#comments Wed, 17 Feb 2010 09:33:00 +0000 admin Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx’s flagship products include Alferon N Injection® (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx’s platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has an extensive number of patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products.

]]> http://healthcarefirms.com/hemispherx-biopharma-inc/feed/ 0 GTC Biotherapeutics, Inc. http://healthcarefirms.com/gtc-biotherapeutics-inc/ http://healthcarefirms.com/gtc-biotherapeutics-inc/#comments Sun, 14 Feb 2010 12:50:41 +0000 admin GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. ATryn®, our recombinant form of human antithrombin, is the first transgenically produced protein to be approved anywhere in the world, having recently been approved by the European Commission for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiencies that are undergoing surgical procedures. ATryn® is produced in the milk of goats developed using micro-injection technology to incorporate a human antithrombin transgene. In addition to ATryn®, GTC is developing additional recombinant forms of therapeutic proteins normally found in human blood plasma as well as monoclonal antibodies. These products have potential applications in hematology, oncology, and autoimmune diseases.

]]> http://healthcarefirms.com/gtc-biotherapeutics-inc/feed/ 0 Dyax Corp. http://healthcarefirms.com/dyax-corp/ http://healthcarefirms.com/dyax-corp/#comments Sun, 14 Feb 2010 12:50:41 +0000 admin Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company utilizes its proprietary drug discovery technology, phage display, to identify antibody, small protein and peptide compounds for clinical development. Dyax also leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Dyax is headquartered in Cambridge, Massachusetts.

]]> http://healthcarefirms.com/dyax-corp/feed/ 0 Biogen Idec Inc. http://healthcarefirms.com/biogen-idec-inc/ http://healthcarefirms.com/biogen-idec-inc/#comments Fri, 12 Feb 2010 23:21:08 +0000 admin http://healthcarefirms.com/?p=133 Biogen Idec is a global biotechnology company that creates new standards of care in therapeutic areas with high unmet medical needs. Our business strategy is focused on discovering and developing first-in-class or best-in-class products that we can deliver to specialty markets globally. Patients worldwide benefit from Biogen Idec’s significant products that address medical needs in the areas of neurology, oncology and immunology.

]]> http://healthcarefirms.com/biogen-idec-inc/feed/ 0 AutoImmune Inc. http://healthcarefirms.com/autoimmune-inc/ http://healthcarefirms.com/autoimmune-inc/#comments Fri, 12 Feb 2010 22:44:05 +0000 admin http://healthcarefirms.com/?p=118 AutoImmune Inc. is a biopharmaceutical company developing products to treat autoimmune and other cell-mediated inflammatory conditions. Several of these products are based on a biological mechanism known as oral tolerance, which provides tissue specific immunosuppression without toxicity or significant side effects.

]]> http://healthcarefirms.com/autoimmune-inc/feed/ 0 AEterna Zentaris Inc. http://healthcarefirms.com/aeterna-zentaris-inc/ http://healthcarefirms.com/aeterna-zentaris-inc/#comments Fri, 12 Feb 2010 18:08:14 +0000 admin http://healthcarefirms.com/?p=78 Æterna Zentaris Inc. (TSX: AEZ, NASDAQ: AEZS) is a late-stage drug development company specialized in oncology and endocrinology.

]]> http://healthcarefirms.com/aeterna-zentaris-inc/feed/ 0